You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cystic fibrosis

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

  • Technology appraisal guidance
  • Reference number: TA276
  • Published:  27 March 2013
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
25 January 2013
(558.35 Kb 42 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 23 January 2013

Back to top